10x Genomics: Premium-Priced Tools, Unproven Earnings Power

The Quarter in Context

10x Genomics closed the second quarter of fiscal 2026 with $151.0M of revenue, down 12.6% from the prior-year quarter's $172.9M. The headline decline is almost entirely a base-effect distortion. License and royalty revenue fell from $27.8M to $1.9M because the prior-year quarter absorbed one-time royalties of $27.3M tied to the Bruker patent-litigation settlement. Strip out that non-recurring line and the underlying products-and-services business actually grew: consumables revenue was the dominant contributor, while instruments revenue dropped 47% to $7.7M and services revenue rose 26% to $10.7M. The filing also records a smaller $3.4M gain on settlement from the Takara litigation, which partly cushioned operating income.

Operating income swung from a $30.1M profit a year ago to a $19.6M loss. That gap is not a sign of operating deterioration so much as a return to a more ordinary level of litigation noise. Net loss for the quarter was $17.9M, a diluted loss per share of $0.14, against diluted weighted-average shares of 130.0M. Management expects, excluding non-recurring license and royalty items, revenues to moderately increase in 2026 versus 2025 and operating expenses to modestly decrease.

Business Model and Profit Engine

Customers are research scientists at academic, translational and biopharma institutions who buy 10x's single-cell and spatial-biology workflows. They pay for three integrated layers: capital instruments (Chromium X series, Visium CytAssist, Xenium Analyzer), the proprietary microfluidic chips, slides and reagents that are consumed on those instruments, and bundled software. Revenue is recognized when instruments and consumables ship, while extended service agreements are recognized ratably. The consumables layer is the recurring engine. In the first half of 2026, consumables revenue rose 10% year-over-year to $260.6M, instruments revenue fell 35% to $18.9M, and services revenue grew 21% to $19.5M. License and royalty revenue, including litigation settlements, fell 94% to $2.9M.

The profit engine runs on three levers. First, gross margin reached 74% in the quarter, helped by tariff refunds, lower inventory write-downs, lower warranty costs and product-mix effects. Second, operating expenses remain heavy: research and development of $56.8M and selling, general and administrative of $78.7M together absorbed $135.5M, only partly offset by the $3.4M settlement gain. Third, the company generates roughly $48.3M of stock-based compensation in the first half and $19.6M of depreciation and amortization, so GAAP operating loss overstates cash burn. Working-capital intensity is moderate, with inventory of $52.6M and accounts receivable of $47.5M against deferred revenue of $33.3M total. Capital intensity is light: $3.2M of property and equipment purchases in the first half.

The single largest data gap is segment economics. 10x files as a single operating and reportable segment, so we cannot see product-line profitability, instrument-versus-consumables contribution margin, or geographic split. Customer concentration is also undisclosed beyond the academic and biopharma framing. Observable weaknesses in the profit engine include negative GAAP operating income in three of the last four reported quarters and persistent use of equity comp to retain staff while operating cash flow carries the franchise.

Earnings Quality and Cash Conversion

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items.

Reported earnings understate the underlying cash machine. Operating cash flow for the first half of 2026 was $43.1M, compared with $52.1M in the first half of 2025. The decline reflects lower non-cash adjustments (less stock-based compensation) and a swing in working-capital items, primarily a $32.1M cash inflow from a year-end receivables balance related to the Bruker settlement. Operating cash flow for the trailing twelve months was $127.1M against $130.6M a year earlier. Capital expenditure was $3.2M in the first half, so the resulting trailing-twelve-month accounting free-cash-flow proxy of $121.4M represents operating cash flow minus total capital expenditure. This is an accounting proxy; the filings do not split maintenance from growth capex.

Stock-based compensation is the largest single non-cash item and deserves attention. It was $48.3M in the first half, roughly 16% of revenue, which dilutes per-share economics. Diluted weighted-average share count rose to 130.0M in Q2 2026 from 124.5M a year earlier, a 4.4% increase. No share repurchases or dividends were recorded in the available history. Working-capital movements were a tailwind in the first half of 2026, with $32.1M of other-receivables collection, but the year-ago comparison benefited from a $68.5M working-capital outflow tied to the same Bruker receivable. Cash conversion looks dependable, but a portion of the operating cash flow improvement over 2024 reflects one-off litigation timing rather than recurring run-rate earnings power.

Business Quality, Moat, and Industry Position

On the available evidence, the company is best described as an important participant, not a demonstrated core supply-chain bottleneck. This classification describes strategic position only; it is not independent proof of a moat or valuation upside.

10x sells specialized tools to life-sciences researchers and competes in single-cell and spatial analysis. Direct competitors include Bruker, which was on the other side of recent litigation, and emerging players in spatial biology. The moat evidence is mixed. On one side, 10x reports that more than 10,000 peer-reviewed publications reference its products, and it sold 1,007 instruments and 424,000 consumable reactions in 2025. Switching costs are real because instruments are typically accompanied by validated consumables and software pipelines. On the other side, the quarter shows instrument revenue falling 47% year-over-year, which is a warning sign that platform refresh cycles can be lumpy and that new entrants can take share. Gross margin of 74% suggests differentiated pricing power, but the operating loss shows that pricing power has not yet translated into recurring operating profitability.

The industry's structural feature is that research funding ultimately drives demand. Management's litigation-driven license revenue is lumpy and non-recurring, and the company's revenue growth is therefore best understood as a function of academic and biopharma R&D budgets. The recent acquisition of Proteintech Genomics for $6.1M is small and intended to extend the proteomics offering; the larger Scale Bio acquisition closed in 2025 and brought contingent consideration of up to $30M still on the table. Together these suggest a company that is investing to broaden its platform, not one that is harvesting a closed moat.

Management and Capital Allocation

Capital allocation has been disciplined on the cash side and aggressive on the equity side. The company finished Q2 2026 with $502.5M of cash and equivalents and $49.5M of marketable securities, totaling roughly $552M of liquidity, and no interest-bearing debt of consequence. Management also paid $10.0M of cash plus $8.7M of stock for a Scale Bio milestone, with up to $30.0M more contingent. No buybacks or dividends are recorded in the available history.

The equity side of the balance sheet carries more risk. The accumulated deficit reached $1.54B at quarter-end. Stock-based compensation of $48.3M in the first half continues to dilute shareholders, and the 4.4% year-over-year increase in diluted shares reduces per-share value for any given level of cash generation. Management has chosen to retain staff and invest in R&D rather than return cash, which is a coherent choice for a growth-stage tools franchise, but it leaves investors reliant on capital markets being supportive if operating losses persist.

Valuation and What the Market Already Expects

Same-date cash and debt components are unavailable, so no current net-cash or net-debt adjustment is used in the valuation bridge.

The dated market capitalization is $5.97B at a share price of $47.03, with the market data stamped 2026-08-03. The trailing-twelve-month accounting free-cash-flow proxy is $121.4M, which implies a free-cash-flow yield of roughly 2.0% on the current enterprise value. Because the available balance-sheet snapshot is too old to form a clean net-cash figure for the latest quarter, no balance-sheet adjustment is included in the equity bridge; this is a limitation rather than an analyst assumption.

The qualitative implication is that the current market capitalization appears to require double-digit revenue growth, durable mid-70s gross margins, and meaningful operating-leverage expansion from a franchise that has produced exactly one profitable year of recent operating income and a negative operating margin in three of the last four reported quarters. The current free-cash-flow yield of around 2% is not, by itself, a margin of safety. A 10% free-cash-flow yield would correspond to a market capitalization of roughly $1.2B, which is far below today's $5.97B; the implied growth and margin path the market is pricing therefore looks demanding given the operating-loss history.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is the normalized SEC cash-flow proxy, while every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and a same-date balance-sheet adjustment when available. If current cash and debt facts do not share one report date, the table shows the adjustment as unavailable and conservatively applies zero. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly 16.8% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. Negative margin of safety means the current market capitalization exceeds the scenario value.

Five Value-Investing Lenses

Benjamin Graham Lens

Graham's discipline asks whether the price offers a margin of safety against a defensible, normalized earnings power. The company reports a trailing-twelve-month operating loss of $88.4M, so a Graham-style test on a multiple of normalized earnings fails on the earnings input alone. The balance sheet is supportive: roughly $552M of cash and marketable securities against minimal interest-bearing debt. However, Graham also stressed that a famous company or a falling share price is not itself evidence of cheapness. The dated $47.03 price implies that the market is paying for several years of normalized growth and margin expansion that the operating record does not yet show.

Benjamin Franklin Lens

Franklin's modern application is thrift, compounding and opportunity cost. 10x compounds cash conservatively on the right-hand side of the balance sheet, with marketable securities producing $9.8M of interest income in the first half. On the left-hand side, stock-based compensation of $48.3M in the first half is a non-cash but real cost: it dilutes existing shareholders at roughly 4.4% per year. The opportunity-cost question is what per-share value would look like if management issued fewer equity awards and accepted slower hiring. Until that trade-off is visible, the franchise looks like a fair compounding machine whose per-share economics are being partly spent on talent.

Warren Buffett Lens

Buffett's lens would focus on owner earnings, moat and the honesty of capital allocation. The accounting free-cash-flow proxy is $121.4M on a trailing basis, but Buffett would want to understand maintenance capex, which the filings do not separate from growth capex. The moat evidence is mixed: more than 10,000 publications reference the products, but instrument revenue fell 47% in Q2 2026, suggesting that competitive pressure or refresh-cycle lumpiness can dent near-term economics. Capital allocation shows discipline in avoiding debt and in keeping the M&A checks small, but the reliance on stock comp dilutes long-term per-share value.

Charlie Munger Lens

Munger would invert the thesis. What could permanently destroy value? The most plausible path is a combination of revenue growth slowing to single digits while operating expenses stay elevated, which would push the company toward sustained cash burn and a future equity raise at a lower price. The obvious incentive trap is that stock-based compensation rewards revenue and headcount growth without a clean link to per-share value. The bias to watch is the temptation to treat the litigation windfall as recurring; the filing explicitly flags that license and royalty revenue is non-recurring and tied to settlements.

Li Lu Lens

Li Lu would ask whether 10x sits inside his circle of competence. The business is intelligible: tools for biologists that generate consumables revenue, with pricing power visible in a 74% gross margin. Culture evidence is positive in some respects: insider-trading policies, small M&A checks, and a stated commitment to R&D. What Li Lu would want more of is durable advantage evidence across cycles; a single quarter with instruments down 47% is exactly the kind of data point that should give a long-term holder pause. Risk control at 10x is excellent on the balance-sheet side and weaker on the dilution side.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

Three observable thesis breakers stand out. First, a return to positive operating income in two consecutive quarters with operating margin above 5% would force a re-rating higher. Second, sustained double-digit revenue growth excluding license and royalty items, combined with stable 70%+ gross margins, would justify a richer valuation. Third, a material share repurchase program using the $552M liquidity balance would signal that management views the stock as cheap and would change the dilution story.

The most likely wrong assumption is that the market's current valuation already prices in normalized growth and margin expansion. The filings show that license and royalty revenue collapsed 93% year-over-year in Q2 and that consumables growth of 10% in the first half is the closest thing to a clean growth signal. If the dated market capitalization is more than 20% above the deterministic base-case valuation, the implication is that investors are paying a premium that requires a bull-case operating outcome.

Investment Conclusion

The franchise has real technology, a defensible 74% gross margin, and a fortress balance sheet with roughly $552M of liquidity and no material debt. Against that, GAAP operating income is negative in three of the last four reported quarters, instruments revenue fell 47% in the latest quarter, and equity dilution from stock-based compensation continues at roughly 4.4% per year. The dated $47.03 share price implies a market capitalization of $5.97B, which sits well above the deterministic base-case valuation in the analytical record and would require an operating outcome closer to the bull-case scenario. The free-cash-flow yield of roughly 2% does not provide a margin of safety. Conclusion: Overvalued.

This article is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.